XML 28 R14.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 8 - Accrued Liabilities | 6 Months Ended
--- | ---
Jun. 30, 2026
Notes to Financial Statements |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] |
8. | Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):
|  | June 30, 2026 |  |  | December 31, 2025 |
Clinical trial costs |  | $ | 1,823 |  |  | $ | 1,291 |
Compensation |  |  | 1,205 |  |  |  | 1,380 |
Research and development services |  |  | 467 |  |  |  | 749 |
Professional services fees |  |  | 165 |  |  |  | 120 |
Other |  |  | 6 |  |  |  | 5 |
Total accrued liabilities |  | $ | 3,666 |  |  | $ | 3,545 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration